BiotechTube

SER-252 (PEOZ-apomorphine)

Phase 1Recruiting
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

PARKINSON DISEASE (Disorder)

Conditions

PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease

Trial Timeline

Feb 1, 2026 → Jan 31, 2027

NCT ID
NCT07422675

About SER-252 (PEOZ-apomorphine)

SER-252 (PEOZ-apomorphine) is a phase 1 stage product being developed by Serina Therapeutics for PARKINSON DISEASE (Disorder). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07422675. Target conditions include PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease.

What happened to similar drugs?

20 of 20 similar drugs in PARKINSON DISEASE (Disorder) were approved

Approved (20) Terminated (3) Active (0)
✅Mirabegron + PlaceboAstellas PharmaApproved
✅Lemborexant + placeboEisaiApproved
✅Safinamide MesilateEisaiApproved
✅Istradefylline PillKyowa KirinApproved
✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved
✅Carbidopa/levodopa/entacaponeNovartisApproved
✅Carbidopa/levodopa/entacapone + Immediate release carbidopa/levodopaNovartisApproved

Hype Score Breakdown

Clinical
6
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07422675Phase 1Recruiting

Competing Products

20 competing products in PARKINSON DISEASE (Disorder)

See all competitors
ProductCompanyStageHype Score
exidavnemab + Placebo ComparatorBioArctic ABPhase 2
36
UB-312 + PlaceboVaxxinityPhase 1
19
NAV5001 + DaTscanNavidea BiopharmaceuticalsPhase 3
22
LY4006896 + PlaceboEli LillyPhase 1
36
ATH-1017 + PlaceboLeonaBioPhase 2
17
piclozotan + 0.9% sodium chloride (normal saline)Daiichi SankyoPhase 2
35
Mirabegron + PlaceboAstellas PharmaApproved
43
E2007EisaiPhase 3
32
ARICEPTEisaiPhase 3
40
PerampanelEisaiPhase 3
32
GPI 1485EisaiPhase 2
35
E2007EisaiPhase 3
40
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior PlaceboEisaiPhase 3
40
Equfina 50 mgEisaiPre-clinical
26
EqufinaEisaiPre-clinical
26
perampanel + placeboEisaiPhase 2
27
Lemborexant + placeboEisaiApproved
50
Placebo + E2007 + E2007EisaiPhase 3
32
Safinamide MesilateEisaiApproved
43
E2007 + E2007 + E2007EisaiPhase 2
35